This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List
by Zacks Equity Research
The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.
NVOPositive Net Change LLYPositive Net Change HIMSNegative Net Change
biotechs medical pharmaceuticals
ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?
by Ekta Bagri
ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change
biotechs
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change
biotechs
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
by Zacks Equity Research
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
ALNYPositive Net Change JNJPositive Net Change VNDANegative Net Change ANIPNegative Net Change
biotechs
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
by Zacks Equity Research
LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.
ALNYPositive Net Change ANIPNegative Net Change XENEPositive Net Change
biotechnology biotechs medical pharmaceuticals
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
by Zacks Equity Research
Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.
AZNPositive Net Change ALNYPositive Net Change ANIPNegative Net Change RPTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
by Zacks Equity Research
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
ALNYPositive Net Change BMYPositive Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
by Zacks Equity Research
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
PFEPositive Net Change BMRNNegative Net Change NVOPositive Net Change QUREPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
by Zacks Equity Research
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
XENEPositive Net Change AXSMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
by Zacks Equity Research
GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.
GSKPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs pharmaceuticals
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
by Zacks Equity Research
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
JAZZPositive Net Change ACADPositive Net Change AXSMPositive Net Change
biotechs
QIAGEN's TB Testing Business Gets New Exposure at Global Summit
by Zacks Equity Research
QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.
ABTPositive Net Change HOLXNegative Net Change QGENPositive Net Change RVTYPositive Net Change
biotechnology biotechs medical
5 Stocks With Recent Price Strength Amid October Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.
CORTNegative Net Change ADMAPositive Net Change QFINNegative Net Change VRTPositive Net Change ATATPositive Net Change
biotechs business-services computers consumer-discretionary medical
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
by Zacks Equity Research
New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.
GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechs
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
by Zacks Equity Research
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
REGNPositive Net Change BAYRYPositive Net Change KODPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
by Zacks Equity Research
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
REGNPositive Net Change SNYPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
by Zacks Equity Research
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
ILMNPositive Net Change MYGNNegative Net Change EXASPositive Net Change VCYTPositive Net Change
biotechs medical
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
by Zacks Equity Research
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
by Zacks Equity Research
PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.
ALNYPositive Net Change PTCTPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
by Ahan Chakraborty
Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.
VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
by Zacks Equity Research
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
ALNYPositive Net Change ANIPNegative Net Change ACADPositive Net Change SLNONegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Gains 13.5% Year to date: How to Play the Stock?
by Zacks Equity Research
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
REGNPositive Net Change ALNYPositive Net Change ANIPNegative Net Change NTLAPositive Net Change
biotechs
Zacks Initiates Coverage of Earth Science Tech With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Earth Science Tech as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ETST's promising growth prospects and financial health amid market challenges.
ETSTPositive Net Change
biotechs medical